News & Videos - OPKO HEALTH INC.

You are currently viewing all stock exchange news of the financial instrument OPKO HEALTH INC. regarding all markets in all languages.

> News03/17/2025 - 12:00 GlobeNewsWire published a news.

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders 03/17/2025 - 12:00• • GlobeNewsWire • Stocks

MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO’s proprietary long-acting oxyntomodulin...

Thank you Chart

> News02/27/2025 - 21:10 GlobeNewsWire published a news.

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results 02/27/2025 - 21:10• • GlobeNewsWire • Stocks

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study ( NCT06655324 ) of an EBV vaccine candidate being developed in collaboration with Merck....

Thank you Chart

> News02/13/2025 - 21:05 GlobeNewsWire published a news.

OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 02/13/2025 - 21:05• • GlobeNewsWire • Stocks

MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27 th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION...

Thank you Chart

> News01/09/2025 - 16:45 GlobeNewsWire published a news.

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference 01/09/2025 - 16:45• • GlobeNewsWire • Stocks

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 43 r d Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 15 th at 3:00 p.m. Pacific time. The presentation will be webcast live and available for replay in the Investors section of OPKO...

Thank you Chart

> News01/07/2025 - 13:00 GlobeNewsWire published a news.

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck 01/07/2025 - 13:00• • GlobeNewsWire • Stocks

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosis There are no current treatments or vaccines for EBV First participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), announces dosing of the first participant in the Phase I study ( NCT06655324 ) of an EBV...

Thank you Chart

> News11/20/2024 - 13:00 GlobeNewsWire published a news.

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference 11/20/2024 - 13:00• • GlobeNewsWire • Stocks

MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 36 th Annual Healthcare Conference, being held December 3-5, 2024 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, December 4 th at 1:30 p.m. Eastern time. The fireside chat will be webcast live and available for replay in the...

Thank you Chart

> News11/07/2024 - 21:05 GlobeNewsWire published a news.

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results 11/07/2024 - 21:05• • GlobeNewsWire • Stocks

MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million . OPKO completed the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health, excluding...

Thank you Chart

> News10/29/2024 - 20:05 GlobeNewsWire published a news.

OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 10/29/2024 - 20:05• • GlobeNewsWire • Stocks

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7 th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION...

Thank you Chart

> News10/07/2024 - 12:00 GlobeNewsWire published a news.

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program 10/07/2024 - 12:00• • GlobeNewsWire • Stocks

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional...

Thank you Chart

> News09/23/2024 - 12:00 GlobeNewsWire published a news.

OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development 09/23/2024 - 12:00• • GlobeNewsWire • Stocks

WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. “Dr. Abbadessa’s deep experience in leading early-stage oncology...

Thank you Chart

> News09/16/2024 - 11:30 PR Newswire published a news.

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health 09/16/2024 - 11:30• • PR Newswire • Stocks

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health PR Newswire BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company,...

Thank you Chart

> News08/07/2024 - 20:06 GlobeNewsWire published a news.

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results 08/07/2024 - 20:06• • GlobeNewsWire • Stocks

MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001 , a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while minimizing the likelihood of antigen escape. This...

Thank you Chart

> News08/01/2024 - 20:05 GlobeNewsWire published a news.

OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 08/01/2024 - 20:05• • GlobeNewsWire • Stocks

MIAMI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Wednesday, August 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 7 th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO...

Thank you Chart

> News07/18/2024 - 12:00 GlobeNewsWire published a news.

OPKO Health Announces $100 Million Share Repurchase Program 07/18/2024 - 12:00• • GlobeNewsWire • Stocks

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common stock from time to time through open market purchases, block trades, privately negotiated transactions, accelerated share repurchase transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable...

Thank you Chart

> News07/17/2024 - 20:14 GlobeNewsWire published a news.

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments 07/17/2024 - 20:14• • GlobeNewsWire • Stocks

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA ™ , a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. “This transaction with HCRx allows OPKO to retain a significant portion of NGENLA's profit share...

Thank you Chart

> News05/31/2024 - 14:48 GlobeNewsWire published a news.

OPKO Health to Participate in the Jefferies Global Healthcare Conference 05/31/2024 - 14:48• • GlobeNewsWire • Stocks

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6 th at 10:30 a.m. Eastern time. The fireside chat will be webcast live and available for replay in the Investors section of...

Thank you Chart

> News05/07/2024 - 20:05 GlobeNewsWire published a news.

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results 05/07/2024 - 20:05• • GlobeNewsWire • Stocks

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health, excluding operations in New York and New Jersey,...

Thank you Chart

> News05/03/2024 - 12:00 GlobeNewsWire published a news.

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 05/03/2024 - 12:00• • GlobeNewsWire • Stocks

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7 th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages...

Thank you Chart

> News03/05/2024 - 13:52 GlobeNewsWire published a news.

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV 03/05/2024 - 13:52• • GlobeNewsWire • Stocks

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human...

Thank you Chart

> News02/27/2024 - 21:05 GlobeNewsWire published a news.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results 02/27/2024 - 21:05• • GlobeNewsWire • Stocks

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies, with expectations for one oncology program...

Thank you Chart